12:00 AM
Feb 23, 2009
 |  BC Week In Review  |  Company News  |  Deals

Cellartis, AstraZeneca deal

The partners will develop drug safety and screening systems based on human embryonic stem cell (hESC) derived hepatocytes and cardiomyocytes under an expanded research deal to...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >